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Abstract Purpose To monitor the metabolic effects of an
individual patient-tailored, experimental glioma therapy
regimen that included repetitive multiple neurosurgical
resections, radiosurgical interventions, and an adjuvant
maintenance therapy based on the tyrosine kinase inhibitor
imatinib in combination with the chemotherapeutic agent
hydroxyurea (HU). Procedures Therapeutic effects were
monitored in a 26-year-old male patient with a glioblas-
toma multiforme by multimodal imaging using sequential
L-[methyl-(11)C]-methionine positron emission tomogra-
phy (MET–PET) and MRI. The normalized MET uptake
and volume of the metabolically active tumor were asses-
sed sequentially. Results The individual patient-tailored,
experimental glioma therapy caused a continuous decline
of metabolically active tumor volume, associated with
clinical remission over a period of more than two years.
Conclusions MET–PET seems to be useful for monitoring
patient-tailored, experimental glioma therapy regimens,
especially when patients are treated with a multi-step
therapeutic regimen. Monitoring and guidance of those
experimental therapy regimens by MET–PET in a larger
patient group are needed to conﬁrm its clinical value.
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Introduction
Since the EORTC 26981 study [1] standard glioblastoma
therapy has become multidimensional involving surgery,
concomitant radio/chemotherapy, and adjuvant chemo-
therapy. However, the beneﬁts of this standard regimen are
modest, and the problem of primary lack of therapeutic
effectiveness or tumor recurrence remains a serious risk for
nearly all patients [1]. Because of the lack of effective
salvage therapies to date, most GBM patients die within
one to two years after diagnosis has been made [2].
Therefore, novel strategies for the treatment of therapy-
refractory GBM are desperately needed. Individual patient-
tailored, experimental glioma therapy regimens might be
one approach to the problem. Evaluating individual thera-
pies has to overcome two main obstacles:
(i) therapy failure needs to be recognized as early as
possible to allow for switching the therapy before the
clinical status worsens;
(ii) multiple therapies may interact, which makes assess-
ment of the individual contribution to the therapeutic
effect more difﬁcult thereby making any interference
with the treatment of GBM patients, in general, more
difﬁcult.
Novel therapeutics targeting activated signal-transduc-
tion pathways are currently evaluated in oncology. Imatinib
mesylate (Gleevec; Novartis Pharmaceuticals, East Hano-
ver, NJ, USA), a selective tyrosine kinase receptor
inhibitor, especially of platelet-derived growth factor
(PDGF) receptors, has established effects against both
hematologic and solid organ cancers [3–5]. Imatinib has
also been evaluated in malignant glioma patients based on
overexpression of PDGF and PDGF receptors [6].
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DOI 10.1007/s11060-008-9790-3Although preclinical studies suggest substantial antiglioma
activity [7, 8] the therapeutic effect of imatinib in malig-
nant glioma trials, e.g. the NABTC 99-08 trial, has been
modest [9]. In contrast, a marked effect of imatinib has
been reported in a small series of GBM patients with tumor
recurrence treated with imatinib plus the chemotherapeutic
agent hydroxyurea (HU), a ribonucleoside diphosphate
reductase inhibitor [10]. Although the precise mechanism
of combining imatinib with HU remains to be elucidated,
clinical studies suggest that signal transduction inhibitors
can enhance the activity of cytotoxic agents [11]; com-
bining a signal transduction inhibitor with a cytotoxic agent
was effective and well tolerated among GBM patients.
Therefore, the combination of imatinib and HU offers the
potential of added value over and above the effects of
neurosurgical intervention and radiosurgery as part of an
individual patient-tailored, experimental glioblastoma
relapse therapy regimen.
Typically, in malignant gliomas during the course of the
disease multiple therapy events like surgery, radiotherapy,
and chemotherapy take place. Because of multiple inter-
ventions, evaluation of the speciﬁc effect of one
therapeutic intervention is very difﬁcult and, therefore,
diagnostic methods which can provide information about
short-term therapeutic effects can be helpful. Monitoring
metabolic changes in tumors may provide an indicator of
tumor response. Tumor resistance may be detected early on
and in the case of tumor resistance to the therapy applied,
another salvage therapeutic option could be tried.
Typically, in malignant gliomas during the course of the
disease multiple therapy events like surgery, radiotherapy,
and chemotherapy take place. Because of multiple inter-
ventions, evaluation of the speciﬁc effect of one
therapeutic intervention is very difﬁcult and, therefore,
diagnostic methods which can provide information about
short-term therapeutic effects can be helpful. Monitoring
metabolic changes in tumors may provide an indicator of
tumor response. Tumor resistance may be detected early on
and in the case of tumor resistance to the therapy applied,
another salvage therapeutic option could be tried.
Metabolic tracers, for example positron emitter-labeled
amino acids, have been proposed as indicators of tumor
activity [12]. Positron emission tomography with L-
[methyl-(11)C]-methionine (MET–PET) has been used to
study the effects of radiotherapy on gliomas [13–16].
Previous studies suggest that monitoring metabolic changes
with MET–PET may provide an objective measure of
response to temozolomide treatment and moreover, it may
enable prediction of clinical outcome in glioma patients
[17]. This makes MET–PET a valuable addition to
conventional (i.e. morphological) MR imaging. One pre-
vious study monitored the effect of chemotherapy with
procarbazine, CCNU, and vincristine in an anaplastic
oligoastrocytoma by repeated MET–PET [18] and high-
lighted the potential of this technique to monitor
chemotherapy. MET–PET provides a more accurate
assessment of extent of the tumor than contrast enhance-
ment of CT or MRI [19–22]. Accumulation of MET is
largely because of carrier-mediated transport, which is not
altered by dexamethasone [19] and enables distinction
between tumor tissue and contrast-enhancing necrosis [23,
24]. MET undergoes a complex metabolism and is incor-
porated into proteins. Therefore, increased uptake is likely
to reﬂect the metabolic needs of brain tumors [25].
We here explore the potential of MET–PET to monitor
an individual patient-tailored, experimental glioma therapy
regimen in combination with an adjuvant maintenance
therapy with imatinib and HU.
Methods
Repetitive PET scans were performed after intravenous
slow bolus injection of 20 mCi (740 MBq) MET. MET
was synthesized according to the method of Berger et al.
[26]. The patient gave written consent to the MET–PET
studies. As described previously [19], a circular region of
interest 8 mm in diameter was placed in the metabolically
most active area of the tumor on images representing
activity 20–60 min after injection as measured using a
Siemens ECAT EXACT or ECAT EXACT HR (Siemens-
CTI, Knoxville, TN, USA). For reference, a circular region
was placed in the unaffected contralateral cortex, and an
uptake index was calculated from the ratio of tumor to
contralateral activity. In addition, the active tumor volume
was measured volumetrically by three-dimensional thres-
holding as the extent of increased MET uptake C1.5 in the
contiguous tumor region, because this threshold had pro-
vided the best separation between tumor and nontumor
lesions in a previous study [19]. Longitudinal data of MET
uptake index and tumor volume were plotted against time
(Fig. 2).
Case presentation
In September 2002, a ﬁrst grand-mal occurred in a 26-year-
old patient. MR imaging showed a tumor-suspicious lesion
in the left parietal lobe. A stereotaxic biopsy in October
2002 provided no signiﬁcant ﬁnding. Neurosurgical
resection and histopathological examination of the lesion in
November 2002 revealed an astrocytoma WHO grade II.
Because of signs of tumor progression with extensive
headache, multiple focal epileptic seizures, and gadolinium
enhancement in MRI, further neurosurgical resection was
necessary in November 2003 (Figs. 1, 3). Histopathological
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123examination of the resected tumor revealed a malignant
transformation to a glioblastoma multiforme WHO grade
IV. After resection, external radiation therapy up to a total
dose of 60 Gy with concomitant temozolomide chemo-
therapy (75 mg per square meter of body-surface area per
day, seven days per week from the ﬁrst to the last day of
Fig. 1 MR images in relation to surgery, radiotherapy, and adjuvant maintenance imatinib and HU therapy
Fig. 2 Longitudinal data with MET–PET images and a plot of the time course of MET uptake index and tumor volume. In the last two MET–
PET scans plotted, all pixels were below the threshold index of 1.5. Thus, there was no detectable tumor volume
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123radiotherapy) was performed from December 2003 to
January 2004 (Fig. 3).
Despite further resection and combined radiochemo-
therapy, an increased metabolic pattern could be observed
(Fig. 2). Subsequently, a daily adjuvant experimental
maintenance therapy with imatinib (600 mg p.o. daily) and
HU (500 mg p.o. daily) was started in February 2004. To
minimize residual tumor volume, a third neurosurgical
resection was performed in March 2004 and the patient
underwent radiosurgery with a gamma knife in August
2004. The adjuvant maintenance therapy with imatinib and
hydroxyurea was continued until April 2007 (Fig. 3).
Additionally, the patient was treated for symptomatic epi-
lepsy with 600 mg oxcarbazepine, for mood stabilization
with 50 mg trimipramine, and for hypothyreoidism with
75 lg levothyroxine per day.
Therapeutic effects of the multiple therapeutic inter-
ventions were monitored clinically and by sequential
MET–PET scans and MR imaging, respectively, during the
observation period from January 2004 until March 2006
(Figs. 1, 2).
Before initiation of imatinib and HU therapy, MET
uptake was increased 1.93-fold compared with the unaf-
fected contralateral tissue (January 2004). In July 2004,
after a daily therapy of imatinib and HU over six months
and neurosurgical resection of residual tumor in March
2004, MET uptake decreased (1.56) and tumor volume
shrank from 14.60 to 3.06 cm
3. Clinically, signs and
symptoms of tumor progression were not observed. In
December 2004, after a therapy duration of eleven months
and additional radiosurgery in August 2004, MET uptake
and the tumor volume were stable (MET uptake 1.57;
tumor volume 3.38 cm
3). In the follow-up MET–PET
examinations after ten months (October 2005), no signiﬁ-
cant MET uptake (C1.5) was detectable; this remained
unchanged until the end of the observation period in March
2006. The pattern of the gadolinium enhancement also
remained unchanged (Figs. 1, 2).
Thirteen months after the end of the observation period
(April 2007), the clinical status of the patient under dis-
continued daily therapy with imatinib and HU was stable,
signs and symptoms of tumor progression were not
observed, and the Karnofsky performance index was 90%.
After the observation period, the slight right-sided spastic
hemiparesis and the hemianopsy to the right remained
unchanged. Further examinations or imaging procedures
after April 2007 were not available.
Discussion
This case demonstrates that MET–PET can be used to
monitor patient-tailored, experimental therapy with multi-
ple neurosurgical resections and radiosurgical interventions
in combination with an adjuvant maintenance therapy
based on imatinib and HU. The therapeutic effect could be
monitored by using MET–PET and could be followed over
the subsequent period of therapy. The observed MET–PET
metabolic pattern during therapy may indicate a continuous
decline of metabolically active tumor volume below the
Fig. 3 Overview of all therapeutic events and MET–PET imaging since diagnosis of GBM was conﬁrmed
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123threshold of signiﬁcant MET uptake (C1.5). The meta-
bolically inactive MET–PET pattern of the tumor was
sustained until the end of the observation period after
almost 2.5 years, and, moreover, clinically after the end of
the observation period. Thus, MET–PET meets the clinical
need for a method that is sufﬁciently sensitive to indicate
therapeutic efﬁcacy and which enables monitoring of the
metabolic tumor pattern during therapy.
Whether the initial decrease of MET uptake and tumor
volume observed after the 2nd MET–PET is an effect of
neurosurgical resection, radiosurgery, or tyrosine kinase
inhibitor-based treatment cannot be differentiated. Like-
wise, whether the observed stable course of the disease
during the observation period is an effect of brachytherapy
or tyrosine kinase inhibitor-based experimental treatment
cannot be differentiated from our data and therefore
requires further study. On the other hand, in a previous
study with GBM patients refractory to chemotherapy and
radiotherapy treated with imatinib and HU (n = 30) a
tumor response (partial or complete response) or a stable
disease lasting at least three months was observed in 57%
of patients [10]. Additionally, in this study the six-month
and two-year progression-free survival rates were 32 and
16%, respectively. Therefore, an adjuvant maintenance
therapy with imatinib and HU might be partially effective.
We accordingly suggest that maintenance therapy based
on imatinib and HU may be part of the multi-faceted
individual glioma therapy. We hypothesize that imaging-
guided multi-step therapeutic regimens may help to realize
long-term survival in selected subpopulations of glioblas-
toma patients. Monitoring and guidance of those
experimental therapy regimens by MET–PET should be
studied in larger patient samples to establish its clinical
value.
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